These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

736 related items for PubMed ID: 12543790

  • 21. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
    Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA, Sausville EA.
    Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505
    [Abstract] [Full Text] [Related]

  • 22. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
    Chai SK, Nichols GL, Rothman P.
    J Immunol; 1997 Nov 15; 159(10):4720-8. PubMed ID: 9366395
    [Abstract] [Full Text] [Related]

  • 23. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
    Molnár L, Losonczy H.
    Orv Hetil; 2002 Oct 20; 143(42):2379-84. PubMed ID: 12440260
    [Abstract] [Full Text] [Related]

  • 24. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.
    Berger DM, Dutia M, Birnberg G, Powell D, Boschelli DH, Wang YD, Ravi M, Yaczko D, Golas J, Lucas J, Boschelli F.
    J Med Chem; 2005 Sep 22; 48(19):5909-20. PubMed ID: 16161995
    [Abstract] [Full Text] [Related]

  • 25. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.
    Jacobberger JW, Sramkoski RM, Frisa PS, Ye PP, Gottlieb MA, Hedley DW, Shankey TV, Smith BL, Paniagua M, Goolsby CL.
    Cytometry A; 2003 Aug 22; 54(2):75-88. PubMed ID: 12879454
    [Abstract] [Full Text] [Related]

  • 26. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST.
    Cancer Res; 2003 Sep 15; 63(18):5716-22. PubMed ID: 14522890
    [Abstract] [Full Text] [Related]

  • 27. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
    Chatain N, Ziegler P, Fahrenkamp D, Jost E, Moriggl R, Schmitz-Van de Leur H, Müller-Newen G.
    Oncogene; 2013 Aug 01; 32(31):3587-97. PubMed ID: 22926520
    [Abstract] [Full Text] [Related]

  • 28. [Effects of anti-ABL tyrosine kinase intrabody on the growth of K562 cells in nude mice].
    Xu D, Song JM, Hu Y, Guo H, Cao DJ, Wang P, Liu H, Zhao CH.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Feb 01; 24(1):11-4. PubMed ID: 12905832
    [Abstract] [Full Text] [Related]

  • 29. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
    Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB.
    Oncogene; 2001 Sep 27; 20(43):6188-95. PubMed ID: 11593427
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.
    Blood; 2004 Oct 15; 104(8):2532-9. PubMed ID: 15256422
    [Abstract] [Full Text] [Related]

  • 31. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Ebos JM, Tran J, Master Z, Dumont D, Melo JV, Buchdunger E, Kerbel RS.
    Mol Cancer Res; 2002 Dec 15; 1(2):89-95. PubMed ID: 12496355
    [Abstract] [Full Text] [Related]

  • 32. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA, Corradi V, Mancini M, Manetti F, Radi M, Schenone S, Botta M.
    ChemMedChem; 2009 Jan 15; 4(1):118-26. PubMed ID: 19039816
    [Abstract] [Full Text] [Related]

  • 33. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.
    Clin Cancer Res; 2007 Feb 15; 13(4):1089-97. PubMed ID: 17317816
    [Abstract] [Full Text] [Related]

  • 34. An update on dual Src/Abl inhibitors.
    Musumeci F, Schenone S, Brullo C, Botta M.
    Future Med Chem; 2012 Apr 15; 4(6):799-822. PubMed ID: 22530642
    [Abstract] [Full Text] [Related]

  • 35. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, Breittmayer JP, Auberger P.
    Oncogene; 2007 Apr 12; 26(17):2445-58. PubMed ID: 17043649
    [Abstract] [Full Text] [Related]

  • 36. Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo.
    Yuan X, Zhang Y, Zhang H, Jin J, Li X, Liu H, Feng Z, Chen X.
    Leuk Res; 2011 Feb 12; 35(2):237-42. PubMed ID: 20739063
    [Abstract] [Full Text] [Related]

  • 37. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J, Myloch S, Nürnberger H, Rossmanith T, Hofmann WK, Hoelzer D, Ottmann OG.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [Abstract] [Full Text] [Related]

  • 38. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
    Zhelev Z, Bakalova R, Ohba H, Ewis A, Ishikawa M, Shinohara Y, Baba Y.
    FEBS Lett; 2004 Jul 16; 570(1-3):195-204. PubMed ID: 15251464
    [Abstract] [Full Text] [Related]

  • 39. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S, Brullo C, Musumeci F, Botta M.
    Expert Opin Investig Drugs; 2010 Aug 16; 19(8):931-45. PubMed ID: 20557276
    [Abstract] [Full Text] [Related]

  • 40. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
    Ramaraj P, Singh H, Niu N, Chu S, Holtz M, Yee JK, Bhatia R.
    Cancer Res; 2004 Aug 01; 64(15):5322-31. PubMed ID: 15289338
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.